AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis

Area of Science:

• Cardiovascular medicine
• Biochemistry
• Molecular biology

Background:

• Cardiovascular disease (CVD) is a leading cause of death, often linked to high cholesterol and atherosclerosis.
• High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with coronary artery disease (CAD) risk.
• HDL-mediated reverse cholesterol transport (RCT) removes cholesterol from tissues for liver elimination.

Purpose of the Study:

• To investigate the therapeutic potential of apoA-I binding protein (AIBP) for treating CAD.
• To explore AIBP's dual role in augmenting HDL functionality and inhibiting angiogenesis.

Main Methods:

• Identification and characterization of apoA-I binding protein (AIBP).
• Assessment of AIBP's effect on HDL functionality and cholesterol efflux.
• Evaluation of AIBP's impact on endothelial cell activation and angiogenesis.

Main Results:

• AIBP was identified as a protein that enhances HDL functionality by accelerating cholesterol efflux.
• AIBP inhibits vascular endothelial growth factor receptor 2 activation in endothelial cells.
• AIBP effectively limits angiogenesis, a process implicated in atherosclerotic plaque growth.

Conclusions:

• AIBP augments HDL-mediated reverse cholesterol transport, potentially reducing cholesterol accumulation.
• AIBP's anti-angiogenic properties may inhibit atherosclerotic plaque progression and vulnerability.
• AIBP presents a promising novel therapeutic target for managing coronary artery disease.